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DELAYED GRAFT FUNCTION DOES NOT HARM THE FUTURE OF DONATION-AFTER-CARDIAC-
DEATH KIDNEY TRANSPLANTS. 
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Detry O. CHU de Sart-Tilman, Service de Chirurgie Abdominale et Transplantation, 4000 Liège, Bel-
gium. 
  
Introduction: Delayed graft function (DGF) occurs more frequently in kidney transplants from donation 
after cardiac death (DCD) than from donation after brain death (DBD). We investigated the effect of 
DGF on post-transplant outcomes in controlled DCD kidney grafts.  
Patients and Methods: This single-center retrospective study recruited 80 controlled DCD kidney allo-
grafts which have been performed at the University Hospital of Sart Tilman, University of Liège, from 
Jan 2005 to Dec 2011.  
Results: Mean patient follow-up was 28.5 months. No primary non-function grafts were encountered. 
DGF rate was 36%. Overall graft survivals between groups with and without DGF were 92.4% and 
95.1% at 1 year, 92.4% and 91.7% at 3 years, and 84.7% and 91.7% at 5 years (p=ns), respectively. 
Patients with and without DGF had the same survival rates at the corresponding time points (92.4% and 
97.1%, 92.4% and 93.7%, and 84.7% and 93.7%, p=ns, respectively). Estimated glomerular filtration 
rate (eGFR) was significantly lower in DGF group compared to non-DGF group at hospital discharge 
(29 vs 42 ml/min, p=0.001) and up to 1 year post-transplant (46 vs 53 ml/min, p=0.045), but the differ-
ence disappeared afterwards (50 vs 48 ml/min at 3 years, and 54 vs 53 ml/min at 5 years, p=ns). DGF 
did not increase the risk of acute rejection or surgical complications. 29.6% of recipients with DGF de-
veloped acute rejection (biopsy-proven rejection and clinically suspected rejection) compared with 
29.2% of recipients without DGF (p=ns). The rate of all surgical complications was 33.3% and 25% in 
recipients with and without DGF (p=ns). However, DGF prolonged significantly the length of hospitaliza-
tion in DGF than non-DGF group (18.9 vs 13 days, p=0.000). Donor BMI & 30 kg/m2 "& 30 
kg/m2 and pre-transplant dialysis duration increased the risk of DGF in a multivariate logistic regression 
analysis.  
Conclusions: Apart from longer hospital stay, DGF had no deleterious impact on the future of DCD 
kidney allografts. Comparable graft and patient survival, renal function, rejection rate and surgical com-






PROGNOSTIC VALUE OF THE ABSENCE OF VIABLE HCC IN NATIVE LIVER AS A NEW PREDIC-
TOR OF TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION. 
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Introduction: Prognostic factors for hepatocellular carcinoma (HCC) recurrence after liver transplanta-
tion (LT) are still a matter of debate. The absence of viable tumor in the native liver, due to high effec-
tiveness of pre-LT loco-regional treatments or liver resection, is an intriguing prognostic factor that had 
never been evaluated before. 
Patient and methods: Between 11/2000 and 10/2010, 196 LT were performed in patients with evi-
dence of HCC on cirrhosis. Forty-six patients (23.5%) did not show any evidence of active residual HCC 
in native liver (Group NVH) while 150(76.5%) patients, showed a viable HCC (Group VH). All patients in 
Group NVH were treated before LT with a multimodal approach combining TACE, liver resection, RFA, 
PEI or Sorafenib, whereas in Group VH, 104 of the 150(69.3%) patients received bridging therapy 
(p<0.001).  
Results: HCC recurrence occurred in none patients in Group NVH (0%) and 23(15.3%) patients in 
Group VH (p=0.007). Liver resection was the best pre-LT treatment able to obtain the no viable HCC at 
explanted liver. 
Conclusions: The histological absence of viable HCC in native liver after LT, due to the high effective-
ness of pre-LT bridging treatments, is a high positive prognostic factor against HCC recurrence after LT. 
 
 
 
 
 
 
